GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (AMEX:ATNM) » Definitions » Quick Ratio

ATNM (Actinium Pharmaceuticals) Quick Ratio : 10.25 (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Actinium Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Actinium Pharmaceuticals's quick ratio for the quarter that ended in Sep. 2024 was 10.25.

Actinium Pharmaceuticals has a quick ratio of 10.25. It generally indicates good short-term financial strength.

The historical rank and industry rank for Actinium Pharmaceuticals's Quick Ratio or its related term are showing as below:

ATNM' s Quick Ratio Range Over the Past 10 Years
Min: 0.78   Med: 8.6   Max: 21.47
Current: 10.25

During the past 13 years, Actinium Pharmaceuticals's highest Quick Ratio was 21.47. The lowest was 0.78. And the median was 8.60.

ATNM's Quick Ratio is ranked better than
81.47% of 1495 companies
in the Biotechnology industry
Industry Median: 3.38 vs ATNM: 10.25

Actinium Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Actinium Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinium Pharmaceuticals Quick Ratio Chart

Actinium Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.89 13.62 11.66 10.44 9.21

Actinium Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.87 9.21 10.59 8.95 10.25

Competitive Comparison of Actinium Pharmaceuticals's Quick Ratio

For the Biotechnology subindustry, Actinium Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinium Pharmaceuticals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Actinium Pharmaceuticals's Quick Ratio falls into.


;
;

Actinium Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Actinium Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(78.263-0)/8.494
=9.21

Actinium Pharmaceuticals's Quick Ratio for the quarter that ended in Sep. 2024 is calculated as

Quick Ratio (Q: Sep. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(79.52-0)/7.755
=10.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actinium Pharmaceuticals  (AMEX:ATNM) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Actinium Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinium Pharmaceuticals Business Description

Traded in Other Exchanges
Address
100 Park Avenue, 23rd Floor, New York, NY, USA, 10017
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Executives
Sandesh Seth director 300 E 93RD STREET, #20-B, NEW YORK NY 10128
Steve O'loughlin officer: VP, Finance and Corporate Dev. 955 HARTMAN RUN ROAD, MORGANTOWN WV 26507
Dale L. Ludwig officer: Chief Scientific Officer 21 FERNWOOD ROAD, ROCKAWAY NJ 07866-2028
Jeffrey W. Chell director 521 MANDALAY AVENUE #708, CLEARWATER BEACH FL 33767
Ajit Shetty director 643 ZEEDIJK, KNOKKE C9 8300
Anil Kapur officer: Chief Commercial Officer 275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Nitya G. Ray officer: Executive Vice President 14 BAYBURY COURT, EAST HANOVER NJ 07936
Mark Stanley Berger officer: Chief Medical Officer 140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Memorial Sloan-kettering Cancer Center 10 percent owner 1275 YORK AVE., NEW YORK NY 10065
Sergio Traversa director 138 CANTERBURY LN, BLUE BELL PA 19422
C. David Nicholson, director 103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Kaushik J Dave director, officer: President and CEO 4 WATER STREET, EDISON NJ 08820
Richard I Steinhart director 125 ELM STREET, NEW CANAAN CT 06840
Ahlb Holdings, Llc 10 percent owner C/O MSKCC, 1275 YORK AVE., NEW YORK NY 10065
Actinium Holdings, Ltd. 10 percent owner C/O /O STERLING MANAGEMENT, LTD., P.O. BOX HM 29, HAMILTON HM CX D0 00000

Actinium Pharmaceuticals Headlines

From GuruFocus